A Phase 3 interventional study of Murepavadin and Two anti-pseudomonal antibiotics in Pneumonia, sponsored by Polyphor Ltd.. Terminated at 61 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Polyphor Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Pneumonia with a site in France — 18 open to participants now, 20 under way, 3 of them phase 3. Pneumonia · France.
Among the 138 studies in Pneumonia with a site in France, this one is the 65th largest by enrollment of the 79 interventional ones that give a count, is one of 9 that started in 2018, is one of 25 in phase 3, and was the 51st registered.
1,566 studies on the registry are indexed under Pneumonia; 266 are open to participants now.
Browse Pneumonia studies →18 of the 138 studies in Pneumonia with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
University Hospital, Caen · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 47 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 32 · Phase 4 3
First in 2003; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 129 across 976 interventional studies indexed under Pneumonia.
Median enrollment 161 across the 79 interventional studies, 227 across the 56 observational. Of the 99 that completed or were terminated, 14 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 138 have an industry lead sponsor. The 10 most frequent:
Polyphor Ltd. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Polyphor Ltd. has 2 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumonia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07439146University Hospital, Clermont-FerrandRisk of Pneumonia in Intubated Patients in Emergency Situations | 2026-12-31 |
| NCT06916481Assistance Publique - Hôpitaux de ParisDefinition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 138 studies in Pneumonia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous murepavadin combined with of one anti-pseudononas antibiotic with that of two anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia (VABP) in adult subjects.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Murepavadin IV + one anti-pseudomonal antibiotic
Drug: Murepavadin
Association of 2 anti-pseudomonal antibiotics
Drug: Two anti-pseudomonal antibiotics
Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Clinical cure rate
Time frame: 21-24 days after start of study treatment
Ran from Mar 2018 to primary completion in Jul 2019, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Murepavadin
Polyphor Ltd.